 | Up a level |
Journal Article
Estenfelder, S., Tausch, E., Huber, H., Bloehdorn, J., Cymbalista, F., Leblond, V., Delmer, A., Ibach, S., Choquet, S., Dartigeas, C., Cazin, B., Tournilhac, O., Pegourie, B., Seiler, T., Soekler, M., Zirlik, K., Alt, J., Schetelig, J., Hallek, M., Dreger, P., Doehner, H. and Stilgenbauer, S. (2016). MUTATION ANALYSIS BY TARGETED NEXT GENERATION SEQUENCING IN ULTRA HIGH RISK CLL PATIENTS TREATED WITHIN THE CLL2O STUDY. Haematologica, 101. S. 228 - 230. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736
Mueller, C., Cymbalista, F., Schweighofer, C., Busch, R., Porcher, R., Langerbeins, P., Cazin, B., Fink, A. -M., Dreyfus, B., Ibach, S., Lepretre, S., Fischer, K., Vehling-Kaiser, U., Eichhorst, B., Bergmann, M. A., Wendtner, C. -M., Stilgenbauer, S., Doehner, H., Leblond, V., Hallek, M. and Levy, V. (2014). Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk Binet stage A chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 37. S. 184 - 185. BASEL: KARGER. ISSN 2296-5262